세계의 수막염균성 수막염 치료 시장 : 치료 유형별, 투여 경로별, 백신 유형별, 유통 채널별, 지역별 - 기회 및 예측(2018-2032년)

Global meningococcal meningitis treatment market is projected to witness a CAGR of 5.50% during the forecast period 2025-2032, growing from USD 436.11 million in 2024 to USD 669.29 million in 2032. The market has witnessed steady growth due to rising awareness of meningococcal infections, enhanced global immunization initiatives, and mounting efforts to improve outbreak response. Meningococcal meningitis is an acute bacterial infection caused by the bacterium Neisseria meningitidis, characterized by a rapid onset and high fatality rates if left untreated. The treatment typically involves the use of potent antibiotics such as penicillin, ceftriaxone, or chloramphenicol, accompanied by supportive treatment.

There are proactive interventions and prevention measures, such as chemoprophylaxis for close contact in areas with endemic outbreaks, that form part of the disease control measures. Government-sponsored immunization campaigns, improved diagnostic availability, and increased research and development expenditures for next-generation vaccines and treatments have further boosted the market's growth.

Increasing Prevalence of Meningococcal Meningitis Boosts Market Demand

The rising cases of meningococcal meningitis are driving market growth by bolstering the demand for effective treatment and vaccination solutions. As per the estimates of the World Health Organization (WHO), approximately 1 in 5 people across the globe who get bacterial meningitis suffer from severe complications and 1 in 6 people affected by the condition die. Since the disease remains a major public health concern with periodic outbreaks in many areas, governments and healthcare bodies globally are giving utmost importance to immunization campaigns to mitigate its impact. This has resulted in broader vaccine coverage and enhanced awareness campaigns, which are driving higher vaccination rates. Pharmaceutical companies are investing in the formulation of new and combination vaccines that offer broader protection from several meningococcal serogroups, thereby increasing vaccine uptake and compliance. Advances in diagnostic technologies also make the disease easier to detect and provide timely treatment, thereby fueling the market growth.

Increasing Emphasis on Innovation Supports Market Expansion

Technological developments and innovations in treatment regimens are the key drivers of the global meningococcal meningitis treatment market; however, there is an emerging trend of combination therapies which provide increased coverage against resistant strains and reduce regimen failures. Major pharma players are devoting greater attention to the development of newer antibiotic classes with greater efficacy and fewer side effects, resulting in the availability of advanced vaccines.

For instance, in February 2025, GlaxoSmithKline plc's Penmenvy, a 5-in-1 meningococcal vaccine targeting serogroups A, B, C, W, and Y, was approved by the United States Food and Drug Administration (US FDA) for individuals aged 10 to 25 years. Combining components of the company's existing Bexsero and Menveo vaccines, Penmenvy offers broad protection against invasive meningococcal disease (IMD) with fewer injections, aiming to improve vaccination rates.

At the same time, clinical practice guidelines are shifting the focus to antimicrobial stewardship and preventing the misuse of antibiotics. Hospitals and medical professionals alike are implementing stewardship programs that include timely diagnostic workups, optimal drug choice, and ongoing monitoring of clinical outcomes. This balanced strategy ensures improved patient care and reduces the development of antibiotic-resistant forms of the meningococcus.

Hospital Pharmacies Account for a Significant Share of the Market

Hospital pharmacies dominate the global market for treating meningococcal meningitis, with most treatment regimens starting with emergency treatments. Hospital environments play a critical role in the provision of parenteral antibiotics, the management of acute symptoms, and the stabilization of patients. Intensive care and close monitoring are necessary for many cases of meningitis, solidifying the status of hospital-administered treatment. Therefore, global health systems are focusing on improving hospital preparedness with investments in pharmacy automation, medicine stockpiling, and staff training. Additionally, leading hospital pharmacies are actively expanding their market reach, driving growth within this segment.

For instance, in March 2025, Apollo Health Co Ltd, the company behind the online platform Apollo 24/7 and Apollo Pharmacy, announced plans to expand its offline hospital pharmacy network in Bengal, India.

Meanwhile, retail pharmacies and online platforms are becoming increasingly important channels for prophylactic and follow-up medications in select markets, propelling their expansion.

North America Holds Major Share of Meningococcal Meningitis Treatment Market

North America holds the largest share of the meningococcal meningitis market due to its advanced healthcare infrastructure, high level of awareness for meningococcal diseases, and extensive availability of drugs and vaccines. Over the past few years, the threat of the condition has increased significantly.

For instance, in 2024, 503 probable and confirmed cases of meningococcal disease in the United States were reported, the largest number since 2013. The region receives good support from the government through vaccination activities and public health education that support timely immunization, thereby stimulating demand. Moreover, the presence of major pharma companies that invest heavily in research and development ensures ongoing technological advancements in meningococcal vaccines and treatments.

Meanwhile, Africa remains the most affected region globally, with major governments and healthcare organizations focusing on allocating significant resources to reduce mortality rates and boost treatment delivery.

Impact of the U.S. Tariff on Meningococcal Meningitis Treatment Market

Tariff-induced increases in the prices of active pharmaceutical ingredients (APIs) and medical devices create cascading effects across the treatment ecosystem. The most exposed of these include generic antibiotics that treat meningococcal infections, with narrow profit margins. The increased costs decrease the competitiveness of the manufacturers, and some might be forced to leave the market entirely. The latest tariff spikes in the United States highlight the vulnerabilities of the value chain of treating meningococcal meningitis, pushing the cost of inputs, the risk of supply chains, and uneven global access. Although shifts in manufacturing practices and supply diversification increase resilience, the short-term impact is a reduced supply and higher treatment costs, unless mitigated through strategic global collaboration and supportive domestic policies.

Key Players Landscape and Outlook

The key players in the market are focusing on research and development investments aimed at next-generation vaccines with enhanced safety profiles and larger serogroup coverages. Market growth remains positive with rising vaccination efforts, heightened health awareness, and the availability of better diagnostic technologies for detecting the disease in the initial stages. Public-private partnerships and collaborations with governments and NGOs are improving the availability of vaccines, particularly in high-risk areas. They are also expanding their geographical reach and reinforcing distribution networks to access emerging markets.

For instance, in May 2025, the US FDA approved the expansion of Sanofi's quadrivalent meningococcal vaccine, MenQuadfi, for use in infants as young as six weeks old. Previously, the vaccine was authorized for children two years of age and older. MenQuadfi helps protect against invasive meningococcal disease caused by serogroups A, C, W, and Y.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Antibiotics Therapy
      • 5.2.1.1.1. Third-generation Cephalosporins
      • 5.2.1.1.2. Penicillins
      • 5.2.1.1.3. Other Antibiotics
    • 5.2.1.2. Adjunctive Therapy
  • 5.2.2. Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Parenteral (Injections)
  • 5.2.3. By Vaccine Type
    • 5.2.3.1. Conjugate Vaccines
    • 5.2.3.2. Polysaccharide Vaccines
    • 5.2.3.3. Combination Vaccines
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Online Pharmacies
    • 5.2.4.3. Retail Pharmacies
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Treatment Type
  • 5.3.2. By Route of Administration
  • 5.3.3. By Vaccine Type
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Treatment Type
    • 6.2.1.1. Antibiotics Therapy
      • 6.2.1.1.1. Third-generation Cephalosporins
      • 6.2.1.1.2. Penicillins
      • 6.2.1.1.3. Other Antibiotics
    • 6.2.1.2. Adjunctive Therapy
  • 6.2.2. Route of Administration
    • 6.2.2.1. Oral
    • 6.2.2.2. Parenteral (Injections)
  • 6.2.3. By Vaccine Type
    • 6.2.3.1. Conjugate Vaccines
    • 6.2.3.2. Polysaccharide Vaccines
    • 6.2.3.3. Combination Vaccines
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Hospital Pharmacies
    • 6.2.4.2. Online Pharmacies
    • 6.2.4.3. Retail Pharmacies
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Meningococcal Meningitis Treatment Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.1.1. Antibiotics Therapy
        • 6.3.1.2.1.1.1. Third-generation Cephalosporins
        • 6.3.1.2.1.1.2. Penicillins
        • 6.3.1.2.1.1.3. Other Antibiotics
        • 6.3.1.2.1.2. Adjunctive Therapy
      • 6.3.1.2.2. Route of Administration
        • 6.3.1.2.2.1. Oral
        • 6.3.1.2.2.2. Parenteral (Injections)
      • 6.3.1.2.3. By Vaccine Type
        • 6.3.1.2.3.1. Conjugate Vaccines
        • 6.3.1.2.3.2. Polysaccharide Vaccines
        • 6.3.1.2.3.3. Combination Vaccines
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Hospital Pharmacies
        • 6.3.1.2.4.2. Online Pharmacies
        • 6.3.1.2.4.3. Retail Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Meningococcal Meningitis Treatment Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. Novartis AG
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 22.3.2. GlaxoSmithKline plc
  • 22.3.3. Pfizer Inc.
  • 22.3.4. Sanofi S.A.
  • 22.3.5. Merck & Co., Inc.
  • 22.3.6. Bio-Med (P) Limited
  • 22.3.7. Wockhardt Ltd.
  • 22.3.8. Walvax Biotechnology Co., Ltd.
  • 22.3.9. JN-International Medical Corporation
  • 22.3.10. Hualan Biological Vaccine Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer